HOME >> BIOLOGY >> NEWS
EPA-led group finds same protein that attracts nutrient iron protects lung from particles

So what's DMT1 doing in the liver, kidneys and brain?

BETHESDA, Md. (Oct. 3, 2005) Multi-vitamin products, nutritional supplements and parents tout the need for such mineral elements as calcium, zinc, phosphorus, iron and others.

Iron, for example, is a nutritional prerequisite to power life itself. When blood doesn't get enough iron from the gut, we become anemic. One of the body's coping mechanisms is to produce more of a protein called divalent metal transporter 1 (DMT1) in the gastrointestinal lining cells to bring into the body as much iron as possible. Until recently DMT1 was exclusively studied for its nutritional role in transporting iron.

But put iron or other air-borne particulates into our lungs and they can cause health problems ranging from asthma and acute respiratory distress syndrome to asbestosis and lung cancer.

In a recently-published paper a group of EPA-led lung researchers reported experiments demonstrating for the first time that "DMT1 is essential for the transport and detoxification of some metals associated with an air pollution particle that damages the pulmonary epithelial surface."

The paper "Divalent metal transporter-1 decreases metal-related injury in the lung" appears in the American Journal of Physiology-Lung Cellular and Molecular Physiology, published by the American Physiological Society. Research was performed by Andrew J. Ghio, Lisa A. Dailey, Jacqueline D. Stonehuerner and Michael C. Madden from the U.S. Environmental Protection Agency; Claude A. Piantadosi of Duke University; Xinchao Wang of University of North Carolina; Funmei Yang of University of Texas; and Kevin G. Dolan, Michael D. Garrick and Laura M. Garrick of SUNY-Buffalo.

Lead researcher Andrew Ghio said this breakthrough discovery of DMT1 lung protection could prompt studies of its roles in other organs where it's found. "For instance, DMT1 is in the liver, kidneys and brain, where it's not needed f
'"/>


3-Oct-2005


Page: 1 2 3 4

Related biology news :

1. Neurons for numerosity: Parietal neurons sum up individual items in a group
2. Johns Hopkins Bloomberg School of Public Health, Geisinger launch new environmental research group
3. Research group gets $7 million to pursue new antibiotic agents
4. Gene study shows three distinct groups of chimpanzees
5. No sign that ethnic groups genes cause diabetes, international research team says
6. Fisheries group calls for science-based approach to address climate impacts
7. 20 of worlds 162 grouper species threatened with extinction
8. Genes and groups of genes commonly shared between species, studies show
9. New group of algae discovered: Picobiliphytes
10. The case of the snuggling skunks -- Is it better to brave winter alone or in a group?
11. 1st international study group for new movement discipline

Post Your Comments:
(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
Cached News: